1256584-73-2

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-ethyl-3-iodophenyl)-2-Methylpropanoic acid is used as a key intermediate in the synthesis of Alectinib, a medication designed to inhibit the anaplastic lymphoma kinase (ALK) enzyme. This inhibition is crucial for blocking the resistant gatekeeper mutant, which in turn leads to a reduction in cell growth associated with certain types of cancer.
As an intermediate in the production of Alectinib, 2-(4-ethyl-3-iodophenyl)-2-Methylpropanoic acid contributes to the development of targeted cancer therapies, offering potential benefits for patients with specific genetic mutations that make their cancer resistant to traditional treatments.

Upstream product

• 1247119-83-0 2-(4-ethylphenyl)-2-methyl-propanoic acid 
• 937-30-4 4-ethylacetophenone 
• 826-55-1 2-methyl-2-phenylpropionic acid 
• 85010-92-0 2-(4-ethylphenyl)-2-methyl-1-propanol 
• 91561-14-7 1-chloro-2-(4-ethylphenyl)-2-methylpropane 
• 14387-10-1 (4-ethyl-phenyl)-acetic acid 
• 1585-07-5 1-bromo-4-ethylbenzene 
• 698394-59-1 methyl 2-(4-ethylphenyl)-2-methyl-propanoate 
• 698394-60-4 2-bromo-1-(4-ethylphenyl)-2-methyl-propan-1-one 
• 100-41-4 ethylbenzene 
• 857768-18-4 2-(4-acetyl-phenyl)-2-methyl-propionic acid 
• 57625-74-8 methyl 2-methyl-2-phenylpropionate 

Downstream Products

• 1256580-46-7 C⁽²⁴⁸⁾H₅₄₀₂ 

Relevant academic research and scientific papers

Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)

A series of novel anaplastic lymphoma kinase (ALK) degraders were designed and synthesized based on proteolysis-targeting chimera (PROTAC) technology by linking two alectinib analogs (36 and 37) with pomalidomide through linkers of different lengths and types. The most promising degrader 17 possessed a high ALK-binding affinity and potent antiproliferative activity in the ALK-dependent cell lines and did not exhibit obvious cytotoxicity in ALK fusion-negative cells. More importantly, the efficacy of compound 17 in a Karpas 299 xenograft mouse model was further evaluated based on its ALK-sustained degradation ability in vivo. The reduction in tumor weight in the compound 17-treated group (10 mg/kg/day, I.V.) reached 75.82%, while alectinib reduced tumor weight by 63.82% at a dose of 20 mg/kg/day (P.O.). Taken together, our findings suggest that alectinib-based PROTACs associated with the degradation of ALK may have promising beneficial effects for treating ALK-driven malignancies.

Synthesis method of alectinib hydrochloride intermediate 2-(4-ethyl-3-iodophenyl)-2-methylpropanoic acid

The invention discloses a synthesis method of an alectinib hydrochloride intermediate 2-(4-ethyl-3-iodophenyl)-2-methylpropanoic acid. The method is characterized by comprising the following steps: reacting 4-ethyl acetophenone with a methyl Grignard reag

Preparation method of aromatic hydrocarbon compound

The invention relates to a preparation method of an aromatic hydrocarbon compound, and particularly discloses a preparation method of a compound as shown in a formula I. The preparation method comprises the following step: in trifluoroacetic acid, under the action of triethylsilane, carrying out a reduction reaction as shown in the specification on a compound as shown in a formula II. The invention further discloses a preparation method of the compound 1, wherein the preparation method is simple in raw material, simple and convenient to operate, low in equipment requirement, small in environmental pollution, low in cost and very suitable for industrial production.

Preparation method and intermediate of halogenated aromatic hydrocarbon compound

The invention discloses a preparation method and an intermediate of a halogenated aromatic hydrocarbon compound, wherein the preparation method has the advantages of simple and accessible raw materials, low reagent price, high yield and simple operation,

Method for synthesizing alecensa hydrochloride intermediate 2-(4-ethyl-3-iodophenyl)-2-methylpropanoic acid

The invention discloses a method for synthesizing an alecensa hydrochloride intermediate 2-(4-ethyl-3-iodophenyl)-2-methylpropanoic acid. The method is characterized by comprising steps of carrying out Friedel-Crafts reaction on ethylbenzene and 3-halogen-2-methyl-1-propylene to obtain 1-halogn-2-(4-ethyl phenyl)-2-methylpropane; carrying out reaction on the 1-halogn-2-(4-ethyl phenyl)-2-methylpropane and magnesium to obtain 2-(4-ethyl phenyl)-2-methyl propyl magnesium halide; carrying out reaction on the 2-(4-ethyl phenyl)-2-methyl propyl magnesium halide and oxygen to obtain 2-(4-ethyl phenyl)-2-methyl-1-propyl alcohol; oxidizing the 2-(4-ethyl phenyl)-2-methyl-1-propyl alcohol, sodium hypochlorite and sodium chlorite by the aid of 2,2,6,6-tetramethyl piperidine oxide to obtain 2-(4-ethyl phenyl)-2-methylpropanoic acid; carrying out reaction on the 2-(4-ethyl phenyl)-2-methylpropanoic acid and iodine in the presence of oxidizing agents under acidic conditions to obtain the alecensa hydrochloride intermediate. 2-(4-ethyl-3-iodophenyl)-2-methylpropanoic acid. The 2,2,6,6-tetramethyl piperidine oxide is used as a catalyst. The method has the advantages that the method is easy and convenient to operate, high in yield, low in cost and little in pollution, raw materials for the alecensa hydrochloride intermediate 2-(4-ethyl-3-iodophenyl)-2-methylpropanoic acid are inexpensive and are easily available, and industrial production can be facilitated.

A NOVEL PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF ALECTINIB

The present invention provides a novel process for the preparation of 2-(4-Ethyl-3-iodophenyl)-2-methylpropanoic acid of Formula (I), (I) which is a key intermediate in the synthesis of Alectinib or its salt of Formula (II).

Preparation method of alectinib intermediate

The invention discloses a preparation method of 2-(4-ethyl-3-iodine) phenyl-2-methyl propionic acid as an alectinib intermediate. According to the preparation method, the operation danger class and production cost are reduced by optimizing and improving a

Synthesis method for alectinib hydrochloride intermediate

The invention discloses a synthesis method for an alectinib hydrochloride intermediate. The synthesis method includes the following steps: 1) with 2-bromo-2-methylpropionic acid as an initial raw material, adding thionyl chloride to perform a chlorination reaction to obtain a compound (I); 2) adding ethylbenzene to the compound (I) and adding anhydrous aluminum trichloride as a catalyst to perform a substitution reaction to obtain a compound (II); 3) dissolving the compound (II) in an organic solvent, adding HC(OMe)3 and a catalyst ZnCl2, performing heat reflux until a rearrangement reaction is completely finished to obtain a compound (III); 4) dissolving the compound (III) in an organic solvent, adding iodine and iodic acid to perform a catalytic reaction to generate a compound (IV); and 5) under alkaline condition, hydrolyzing the compound (IV) to produce the target product, alectinib hydrochloride intermediate. The synthesis method is simple in operations, has high yield and is lower in cost.